EASL立场声明:慢性肝病、肝胆肿瘤及肝移植患者的新冠疫苗接种
EASL发布立场声明,指出慢性肝病(尤其肝硬化)、肝胆恶性肿瘤、肝移植候选者及移植后免疫抑制患者感染SARS-CoV-2后重症风险高,应尽早接种疫苗;但此类患者免疫应答可能受损,疫苗保护可能不完全。已获批疫苗在健康人群有短期安全性、免疫原性和有效性证据,但在上述肝病患者中的免疫原性、保护时长和长期安全性数据尚待生成。
要点
- 肝硬化、肝胆肿瘤及肝移植患者感染SARS-CoV-2后重症风险高,应尽早接种疫苗。
- 肝病患者免疫应答可能受损,疫苗即刻和长期保护作用可能不完全。
- 已获批疫苗在肝病特殊人群中的免疫原性、保护时长和长期安全性数据尚缺。
核心结论
- 慢性肝病、肝硬化、肝胆恶性肿瘤、肝移植候选者及移植后免疫抑制患者感染SARS-CoV-2后重症风险高,应尽早接种疫苗。
- 但此类患者免疫应答可能受损,疫苗保护可能不完全,且缺乏在该人群中的免疫原性、保护时长和长期安全性数据。
研究设计与样本
- EASL立场声明,总结慢性肝病、肝硬化、肝胆肿瘤及肝移植受者中疫苗安全性、免疫原性和有效性的数据,并讨论SARS-CoV-2疫苗引入的意义。
主要发现
- 慢性肝病(尤其肝硬化)、肝胆恶性肿瘤、肝移植候选者及移植后免疫抑制患者感染风险增加,SARS-CoV-2感染后肝硬化患者重症风险高。
- 少数SARS-CoV-2疫苗候选者在健康人群中已完成III期安慰剂对照临床试验,证明短期安全性、免疫原性和有效性。
- 美欧监管机构已批准部分疫苗临床使用,但慢性肝病、肝硬化、肝胆肿瘤及肝移植受者中的免疫原性、保护时长和长期安全性信息尚待生成。
临床怎么用
- 对慢性肝病(尤其肝硬化)、肝胆恶性肿瘤、肝移植候选者及移植后免疫抑制患者,应尽早接种SARS-CoV-2疫苗作为重要保护措施。
- 需认识到此类患者免疫应答可能受损,接种后保护作用可能不完全,应关注后续数据更新。
局限性
- 缺乏慢性肝病、肝硬化、肝胆肿瘤及肝移植受者中SARS-CoV-2疫苗的免疫原性、保护时长和长期安全性数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
According to a recent World Health Organization estimate, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, which originated in China in 2019, has spread globally, infecting nearly 100 million people worldwide by January 2021. Patients with chronic liver diseases (CLD), particularly cirrhosis, hepatobiliary malignancies, candidates for liver transplantation, and immunosuppressed individuals after liver transplantation appear to be at increased risk of infections in general, which in turn translates into increased mortality. This is also the case for SARS-CoV-2 infection, where patients with cirrhosis, in particular, are at high risk of a severe COVID-19 course. Therefore, vaccination against various pathogens including SARS-CoV-2, administered as early as possible in patients with CLD, is an important protective measure. However, due to impaired immune responses in these patients, the immediate and long-term protective response through immunisation may be incomplete. The current SARS-CoV-2 pandemic has led to the exceptionally fast development of several vaccine candidates. A small number of these SARS-CoV-2 vaccine candidates have already undergone phase III, placebo-controlled, clinical trials in healthy individuals with proof of short-term safety, immunogenicity and efficacy. However, although regulatory agencies in the US and Europe have already approved some of these vaccines for clinical use, information on immunogenicity, duration of protection and long-term safety in patients with CLD, cirrhosis, hepatobiliary cancer and liver transplant recipients has yet to be generated. This review summarises the data on vaccine safety, immunogenicity, and efficacy in this patient population in general and discusses the implications of this knowledge on the introduction of the new SARS-CoV-2 vaccines.
引用
- Cornberg M, Buti M, Eberhardt CS, et al. EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients. J Hepatol. 2021. PMID: 33563499. doi:10.1016/j.jhep.2021.01.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。